» Articles » PMID: 22229170

Effect of HER-2/neu Over-expression on Prognosis in Gastric Cancer: a Meta-analysis

Overview
Specialty Oncology
Date 2012 Jan 11
PMID 22229170
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Her-2/neu is the most frequently studied molecular target in gastric cancer but its prognostic impact is still equivocal. We therefore conducted a meta-analysis to more precisely estimate its prognostic significance.

Methods: Published studies that investigated between Her-2/neu status and survival were identified. Meta-analysis was performed by Dersimonian-Laird model. Pooled hazard ratio (HR) and its 95% confidence interval (95%CI) were calculated to evaluate the risk of disease.

Results: A total of 19 studies were analyzed by meta-analysis method, cumulative 4342 cases were included. Pooled data of 15 studies using univariate analysis showed worse survival of patient with her-2/neu (+) (pooled HR=1.59, 95%CI: 1.20-2.12), which maintained in 7 studies of multivariate analysis (pooled HR=1.58, 95%CI: 1.18-2.12). The Q statistic test for 15 studies of univariate analysis and for 7 studies of multivariate analysis showed they had heterogeneity (Q=26.98, p=0.019, Q=17.76, p=0.007, respectively).

Conclusion: HER-2/neu over-expression is related to poor prognosis of gastric cancer but has a modest effect on survival in gastric cancer as an independent prognosis factor.

Citing Articles

Insight into Predictors of Cytoreduction Score Following Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy for Gastric Peritoneal Carcinomatosis Improves Patient Selection and Prognostic Outcomes.

Hamed A, Asmar R, Tirukkovalur N, Tcharni A, Tatsuoka C, Jelinek M Ann Surg Oncol. 2024; 32(1):199-208.

PMID: 39382749 DOI: 10.1245/s10434-024-16328-z.


Construction of a prognostic model for autophagy in Wilm's tumor.

Shi H, Zhang M, Zhang Y Pediatr Surg Int. 2024; 40(1):122.

PMID: 38704513 DOI: 10.1007/s00383-024-05712-1.


Study of the Relationship between MMP-2 and MMP-9 and Her2/neu Overexpression in Gastric Cancer: Clinico- Pathological Correlations.

Jafari E, Safinejad S, Dabiri S, Naghibzadeh-Tahami A Asian Pac J Cancer Prev. 2021; 22(3):811-817.

PMID: 33773545 PMC: 8286688. DOI: 10.31557/APJCP.2021.22.3.811.


Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer.

Sun K, Wang Q, Wu Y Oncol Lett. 2020; 20(5):126.

PMID: 32934695 PMC: 7471739. DOI: 10.3892/ol.2020.11985.


Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study.

Franchi M, Tritto R, Torroni L, Reno C, La Vecchia C, Corrao G Cancers (Basel). 2020; 12(6).

PMID: 32630517 PMC: 7352495. DOI: 10.3390/cancers12061691.